Skip to main content

Denovo DB102-02 A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects with High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1¿

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Denovo Biopharma, LLC

Start Date

July 10, 2018

End Date

January 15, 2021
 

Administered By

Duke Cancer Institute

Awarded By

Denovo Biopharma, LLC

Start Date

July 10, 2018

End Date

January 15, 2021